Litcius/Paper detail

Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition

Ioannis Akoumianakis, Ileana Badi, Gillian Douglas, Surawee Chuaiphichai, L Herdman, Nadia Akawi, Marios Margaritis, Alexios S. Antonopoulos, Evangelos K. Oikonomou, Costas Psarros, Nikolaos Galiatsatos, Dimitris Tousoulis, Attila Kardos, Rana Sayeed, George Krasopoulos, Mario Petrou, Uwe Schwahn, Paulus Wohlfart, Norbert Tennagels, Keith M. Channon, Charalambos Antoniades

2020Science Translational Medicine33 citationsDOIOpen Access PDF

Abstract

mice treated with DPP4i. High plasma DPP4 activity and high insulin were additively related with higher cardiac mortality in patients with coronary atherosclerosis undergoing CABG. These findings may explain the inability of aggressive insulin treatment to improve cardiovascular outcomes, raising the question whether vascular insulin sensitization with DPP4i should precede initiation of insulin treatment and continue as part of a long-term combination therapy.

Topics & Concepts

Dipeptidyl peptidase-4Dipeptidyl peptidaseRedoxPharmacologyChemistryDipeptidyl peptidase-4 inhibitorDiabetes mellitusEndocrinologyMedicineInternal medicineType 2 diabetesBiochemistryEnzymeOrganic chemistryCardiovascular Function and Risk FactorsAdvanced Glycation End Products researchCardiovascular, Neuropeptides, and Oxidative Stress Research